Page 31 - RxBound Winter 2015 Extended
P. 31
“The pharmacy program provides a great opportunity Dr. Guru Betageri Receives Patent!
for student pharmacists to participate with faculty on
exciting research projects as they pursue their First unmodified oral-Testosterone replacement therapy
professional degrees,” he said.
“We have had our sights on a top 10 ranking for TesoRx Pharma, LLC, is a specialty pharmaceutical
research funding among private colleges, and we could company founded in 2010 by Dr. Ramachandran “TR”
be as high as No. 5 in the nation when data is officially Thirucote, Mr. Willem A Robberts and WesternU College of
released,” Robinson said. Pharmacy professor and Graduate College of Biomedical
Sciences Associate Dean, Dr. Guru Betageri. This past
Noteworthy awards from the Department of October 2014, TesoRx announced that it has licensed select
Pharmaceutical Sciences include: international rights to TSX-002, the first unmodified oral-
Testosterone replacement therapy, to Aspen Global
• Dr. Arezoo Campbell, associate professor, studies Incorporated (AGI), a wholly owned subsidiary of Aspen
ambient particulate matter neurotoxicity. British Pharmacare Holdings Limited (or “the Aspen Group”).
Petroleum/South Coast Air Quality Management
District funded $577,590 over two years. As part of this agreement, Aspen Group companies will
invest a total of US$15 million in TesoRx, with additional
• Dr. Ying Huang, associate professor, studies novel payments of $80 million to be made to TesoRx, based upon
anticancer drug formulations. FULGENT regulatory and commercial milestones. Additionally, AGI
Therapeutics funded $532,506 (multiple contracts).
will be responsible for developing and commercializing
• Dr. Fadi Khasawneh, associate professor, studies TSX-002.
platelet G-protein coupled receptors. NIH funded TSX-002 is a unique formulation of native Testosterone that
$416,976 over three years.
allows for the uniquely new convenience aspect of oral
• Dr. Sunil Prabhu, professor, associate dean for administration. TesoRx has tested TSX-002 in over 150
academic and student affairs, studies nanotechnology- patients to date and is poised to begin pivotal trials in 2015.
based regimens for pancreatic cancer It has exhibited a favorable safety profile in all of its studies,
chemoprevention. NIH funded $438,000 over three and if approved, TSX-002 will be the first product to orally
years. deliver a native, bio-identical form of the human hormone.
Worldwide sales of currently available Testosterone
• Dr. David Sanchez, assistant professor, studies
immunity against AIDS-associated malignancies. NIH replacement products exceed $2.5 billion.
funded $219,000 over two years. “We are very excited to have secured Aspen as a partner in
the continued development of TSX-002,” said Will
• Dr. Peter Oelschlaeger, assistant professor, studies
bicyclic beta-lactam antibiotic stability against beta- Robberts, President and Chief Financial Officer of TesoRx.
lactamases. NIH funded $144,540 over three years. “TesoRx’s primary intent is to deliver a safe oral-T
treatment that is currently lacking in the burgeoning
“We are very proud of our research accomplishments, testosterone replacement market. We feel that having an
and in particular our success over the past year,” international collaboration with such a great partner
Robinson said. “This growth in research productivity is provides us with validation of the technology and additional
the result of years of investment in our research resources to realize our goal.”
infrastructure, the hiring of excellent faculty,
strengthening of our graduate Master of Science in Aspen is a global supplier of branded and generic
Pharmaceutical Sciences (MSPS) program, and the pharmaceutical products as well as infant milk nutritionals
strategic investment in post-docs who have been able to and consumer healthcare products. The Group has 26
support the research efforts of our funded faculty.” manufacturing facilities at 18 sites on 6 continents and
approximately 10,000 employees. With its extensive basket
of products that provide treatment for a broad spectrum of
Photo (l-r): Sunil Prabhu, BPharm, PhD, Professor of Pharmaceutical Sciences, acute and chronic conditions experienced throughout all
Associate Dean for Academic and Student Affairs, David Sanchez, PhD, stages of life, Aspen continues to increase the number of
Assistant Professor of Pharmaceutical Sciences, Guru Betageri, PhD, Associate lives benefiting from its products, reaching more than 150
Dean, Graduate College of Biomedical Sciences, Professor of Pharmaceutical
Sciences, Peter Oelschlaeger, PhD, Assistant Professor of Pharmaceutical countries across the world.
Sciences, Arezoo Campbell, PhD, Associate Professor of Pharmaceutical TesoRx Pharma, LLC, is a pharmaceuticals company
Sciences, Fadi T. Khasawneh, PhD, BPharm, Associate Professor of
Pharmaceutical Sciences, Ying Huang, PhD, MD, Associate Professor of focused on rapidly developing and commercializing
Pharmaceutical Sciences, and Jeffrey Wang, PhD, Associate Professor of pharmaceutical products in specialty markets.
Pharmaceutical Sciences, Director of Graduate Education
WesternU, College of Pharmacy 29
for student pharmacists to participate with faculty on
exciting research projects as they pursue their First unmodified oral-Testosterone replacement therapy
professional degrees,” he said.
“We have had our sights on a top 10 ranking for TesoRx Pharma, LLC, is a specialty pharmaceutical
research funding among private colleges, and we could company founded in 2010 by Dr. Ramachandran “TR”
be as high as No. 5 in the nation when data is officially Thirucote, Mr. Willem A Robberts and WesternU College of
released,” Robinson said. Pharmacy professor and Graduate College of Biomedical
Sciences Associate Dean, Dr. Guru Betageri. This past
Noteworthy awards from the Department of October 2014, TesoRx announced that it has licensed select
Pharmaceutical Sciences include: international rights to TSX-002, the first unmodified oral-
Testosterone replacement therapy, to Aspen Global
• Dr. Arezoo Campbell, associate professor, studies Incorporated (AGI), a wholly owned subsidiary of Aspen
ambient particulate matter neurotoxicity. British Pharmacare Holdings Limited (or “the Aspen Group”).
Petroleum/South Coast Air Quality Management
District funded $577,590 over two years. As part of this agreement, Aspen Group companies will
invest a total of US$15 million in TesoRx, with additional
• Dr. Ying Huang, associate professor, studies novel payments of $80 million to be made to TesoRx, based upon
anticancer drug formulations. FULGENT regulatory and commercial milestones. Additionally, AGI
Therapeutics funded $532,506 (multiple contracts).
will be responsible for developing and commercializing
• Dr. Fadi Khasawneh, associate professor, studies TSX-002.
platelet G-protein coupled receptors. NIH funded TSX-002 is a unique formulation of native Testosterone that
$416,976 over three years.
allows for the uniquely new convenience aspect of oral
• Dr. Sunil Prabhu, professor, associate dean for administration. TesoRx has tested TSX-002 in over 150
academic and student affairs, studies nanotechnology- patients to date and is poised to begin pivotal trials in 2015.
based regimens for pancreatic cancer It has exhibited a favorable safety profile in all of its studies,
chemoprevention. NIH funded $438,000 over three and if approved, TSX-002 will be the first product to orally
years. deliver a native, bio-identical form of the human hormone.
Worldwide sales of currently available Testosterone
• Dr. David Sanchez, assistant professor, studies
immunity against AIDS-associated malignancies. NIH replacement products exceed $2.5 billion.
funded $219,000 over two years. “We are very excited to have secured Aspen as a partner in
the continued development of TSX-002,” said Will
• Dr. Peter Oelschlaeger, assistant professor, studies
bicyclic beta-lactam antibiotic stability against beta- Robberts, President and Chief Financial Officer of TesoRx.
lactamases. NIH funded $144,540 over three years. “TesoRx’s primary intent is to deliver a safe oral-T
treatment that is currently lacking in the burgeoning
“We are very proud of our research accomplishments, testosterone replacement market. We feel that having an
and in particular our success over the past year,” international collaboration with such a great partner
Robinson said. “This growth in research productivity is provides us with validation of the technology and additional
the result of years of investment in our research resources to realize our goal.”
infrastructure, the hiring of excellent faculty,
strengthening of our graduate Master of Science in Aspen is a global supplier of branded and generic
Pharmaceutical Sciences (MSPS) program, and the pharmaceutical products as well as infant milk nutritionals
strategic investment in post-docs who have been able to and consumer healthcare products. The Group has 26
support the research efforts of our funded faculty.” manufacturing facilities at 18 sites on 6 continents and
approximately 10,000 employees. With its extensive basket
of products that provide treatment for a broad spectrum of
Photo (l-r): Sunil Prabhu, BPharm, PhD, Professor of Pharmaceutical Sciences, acute and chronic conditions experienced throughout all
Associate Dean for Academic and Student Affairs, David Sanchez, PhD, stages of life, Aspen continues to increase the number of
Assistant Professor of Pharmaceutical Sciences, Guru Betageri, PhD, Associate lives benefiting from its products, reaching more than 150
Dean, Graduate College of Biomedical Sciences, Professor of Pharmaceutical
Sciences, Peter Oelschlaeger, PhD, Assistant Professor of Pharmaceutical countries across the world.
Sciences, Arezoo Campbell, PhD, Associate Professor of Pharmaceutical TesoRx Pharma, LLC, is a pharmaceuticals company
Sciences, Fadi T. Khasawneh, PhD, BPharm, Associate Professor of
Pharmaceutical Sciences, Ying Huang, PhD, MD, Associate Professor of focused on rapidly developing and commercializing
Pharmaceutical Sciences, and Jeffrey Wang, PhD, Associate Professor of pharmaceutical products in specialty markets.
Pharmaceutical Sciences, Director of Graduate Education
WesternU, College of Pharmacy 29
